Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Entrada Therapeutics Inc chart...

About the Company

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.

Exchange

NASDAQ

$228M

Total Revenue

140

Employees

$474M

Market Capitalization

-1312.81

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TRDA News

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials

14d ago, source:

Entrada Therapeutics reported a robust cash position of $352 million, a significant increase from the previous year's $188.7 ...

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

2mon ago, source: Stockhouse

Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular ...

Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline

11d ago, source: Business Insider

Ram Selvaraju has given his Buy rating due to a combination of factors related to Entrada Therapeutics Inc’s solid financial position and promising clinical developments. Entrada concluded the fiscal ...

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates

10d ago, source:

The analysts covering Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) delivered a dose of negativity to shareholders ...

Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying

7d ago, source: Business Insider

Don’t forget to check out our premarket coverage here Check This Out: Jim Cramer Likes Amazon More Than This E-Commerce Platform, Calls Chipotle 'The King' Entrada Therapeutics NewsMORE Related Stocks ...

Nkarta announces pricing of stock offering to raise $240.1M

4d ago, source: Seeking Alpha on MSN

Nkarta (NASDAQ:NKTX) announces the pricing of an underwritten offering of 21.01 million shares of its common stock for $10.00 per share and pre-funded warrants to purchase 3 million shares of common ...

Entrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

16d ago, source:

Cash runway extended through the second quarter of 2026 - - $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 - - Completed dosing for third cohort of Phase 1 ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...